© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Experts in the field of differentiated thyroid cancer highlight recent advances in treatment by reviewing two real-world patient scenarios.
April 15th 2022
Expert Marcia Brose, MD, details a clinical scenario wherein a patient is diagnosed with differentiated thyroid cancer and managed with surgical and radiotherapy.
Perspectives on the use of lenvatinib therapy to manage a patient with radioiodine-refractory DTC, preceding broader considerations for sequencing kinase inhibitor therapy.
April 22nd 2022
Reflecting on the first patient scenario of radioiodine-refractory DTC, experts share their considerations for optimally selecting and sequencing therapy in this setting.
A brief discussion on where endocrinologists and oncologists respectively fit into the differentiated thyroid cancer treatment paradigm.
April 29th 2022
Shared insight on selecting appropriate patients for lenvatinib therapy in differentiated thyroid cancer, as well as optimizing dosing strategies in the context of clinical trial data.
Expert advice on addressing adverse events, particularly through dose holds or reduction, in patients on lenvatinib therapy for radioiodine-refractory DTC.
May 6th 2022
Expert Lori Wirth, MD, highlights key points from a second real-world patient scenario of radioiodine-refractory differentiated thyroid cancer.
Reflecting on a real-world patient scenario of DTC, experts consider how they identify radioiodine-refractory disease and when they would initiate systemic therapy.
May 13th 2022
Shared insight on active surveillance practices for patients with radioiodine-refractory DTC and how disease factors play into selection of therapy at time of recurrence.
Before closing out their discussion on radioiodine-refractory DTC management, experts share practical advice for community physicians.